Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 19, 2016 08:03 ET | Source: Bellerophon Therapeutics LLC

Bellerophon Therapeutics Receives EC Certification for New INOpulse® Drug-Device Delivery System

WARREN, N.J., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that it has received EC Certification...
November 12, 2015 06:03 ET | Source: Bellerophon Therapeutics LLC

Bellerophon Reports 2015 Third Quarter Operational and Financial Results

Phase 3 trial for patients with PAH on track to start enrollment by year-end Special Protocol Assessment (SPA) issued by FDA for Phase 3 program Company plans to continue Phase 2 testing in COPD...
September 30, 2015 07:03 ET | Source: Bellerophon Therapeutics LLC

Bellerophon Announces Functional Respiratory Imaging Data From Company Sponsored Clinical Trial of INOpulse(R) in COPD Patients With Pulmonary Hypertension Presented Today at the European Respiratory Society (ERS) International Congress

HAMPTON, N.J., Sept. 30, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, announced that an oral presentation of late-breaking data from...
September 24, 2015 16:30 ET | Source: Bellerophon Therapeutics LLC

Bellerophon Therapeutics Announces Positive Data From Interim Analysis of Phase 2 Long-Term Extension Study of INOpulse(R) for Treatment of Pulmonary Arterial Hypertension

Conference Call/Webcast to Be Held September 25, 2015 at 9:00am ET Interim Data Reinforces Earlier Phase 2 Data and Indicates Sustainability of Benefits for PAH Patients FDA Issues a Special...
September 15, 2015 08:07 ET | Source: Bellerophon Therapeutics LLC

Bellerophon Therapeutics Announces Leadership Team Changes

- Confirms Focus on Developing INOpulse® Nitric Oxide Therapy for Patients with Pulmonary Hypertension - - Headcount and Costs Substantially Reduced - HAMPTON, N.J., Sept. 15, 2015 (GLOBE...
September 03, 2015 16:23 ET | Source: Bellerophon Therapeutics LLC

Bellerophon to Present in Upcoming Investor Conferences

HAMPTON, N.J., Sept. 3, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that Chairman and Chief Executive Officer...
August 13, 2015 18:33 ET | Source: Bellerophon Therapeutics LLC

Bellerophon Reports 2015 Second Quarter Operational and Financial Results

HAMPTON, N.J., Aug. 13, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today reported operational and financial results for the second...
July 29, 2015 06:03 ET | Source: Bellerophon Therapeutics LLC

Bellerophon Therapeutics Expands License Agreement With INO Therapeutics to Develop INOpulse(R) for Three Additional Cardiopulmonary Diseases

HAMPTON, N.J., July 29, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that it has expanded its license agreement with...
July 27, 2015 06:00 ET | Source: Bellerophon Therapeutics LLC

Bellerophon Therapeutics Announces Top-Line Results From PRESERVATION I Clinical Trial for Bioabsorbable Cardiac Matrix (BCM)

HAMPTON, N.J., July 27, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical stage biotherapeutics company with programs focused on the treatment of cardiopulmonary and...
July 01, 2015 07:32 ET | Source: Bellerophon Therapeutics LLC

Bellerophon Therapeutics Announces Management and Board Additions

HAMPTON, N.J., July 1, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced the appointments of Amit Agrawal as Chief...